Armistice Capital’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,000,000
| Closed | -$10.4M | – | 259 |
|
|
2024
Q3 | $10.4M | Sell |
1,000,000
-96,000
| -9% | -$1.26M | 0.17% | 93 |
|
|
2024
Q2 | $14.2M | Sell |
1,096,000
-140,000
| -11% | -$1.89M | 0.18% | 80 |
|
|
2024
Q1 | $21.6M | Sell |
1,236,000
-828,000
| -40% | -$11M | 0.29% | 64 |
|
|
2023
Q4 | $19.4M | Sell |
2,064,000
-36,000
| -2% | -$335K | 0.27% | 62 |
|
|
2023
Q3 | $23.5M | Buy |
2,100,000
+64,000
| +3% | +$1.03M | 0.36% | 50 |
|
|
2023
Q2 | $43.6M | Buy |
2,036,000
+24,000
| +1% | +$708K | 0.63% | 35 |
|
|
2023
Q1 | $81.4M | Sell |
2,012,000
-66,000
| -3% | -$3.15M | 1.17% | 17 |
|
|
2022
Q4 | $96.7M | Buy |
2,078,000
+6,000
| +0.3% | +$274K | 1.69% | 13 |
|
|
2022
Q3 | $107M | Buy |
2,072,000
+2,000
| +0.1% | +$117K | 1.86% | 10 |
|
|
2022
Q2 | $97.8K | Buy |
2,070,000
+946,000
| +84% | +$51.3M | 1.71% | 10 |
|
|
2022
Q1 | $80M | Buy |
1,124,000
+68,000
| +6% | +$4.42M | 1.55% | 12 |
|
|
2021
Q4 | $79M | Sell |
1,056,000
-780,000
| -42% | -$61.2M | 1.29% | 14 |
|
|
2021
Q3 | $104M | Sell |
1,836,000
-164,000
| -8% | -$8.11M | 1.77% | 9 |
|
|
2021
Q2 | $88M | Buy |
2,000,000
+352,000
| +21% | +$17.2M | 1.58% | 11 |
|
|
2021
Q1 | $81.3M | Buy |
1,648,000
+292,000
| +22% | +$14.6M | 1.87% | 10 |
|
|
2020
Q4 | $57.1M | Buy |
1,356,000
+832,000
| +159% | +$36.6M | 1.94% | 12 |
|
|
2020
Q3 | $24M | Buy |
524,000
+200,000
| +62% | +$9.69M | 0.87% | 43 |
|
|
2020
Q2 | $16.3M | Sell |
324,000
-244,000
| -43% | -$12.6M | 0.71% | 50 |
|
|
2020
Q1 | $29.2M | Buy |
568,000
+174,105
| +44% | +$9.28M | 1.81% | 19 |
|
|
2019
Q4 | $24.3M | Sell |
393,895
-186,105
| -32% | -$11.5M | 1.4% | 21 |
|
|
2019
Q3 | $34.8M | Buy |
580,000
+200,000
| +53% | +$14.9M | 2.31% | 13 |
|
|
2019
Q2 | $32.1M | Buy |
380,000
+8,000
| +2% | +$720K | 2.02% | 17 |
|
|
2019
Q1 | $35.5M | Sell |
372,000
-128,000
| -26% | -$11.5M | 1.94% | 14 |
|
|
2018
Q4 | $35.4M | Buy |
500,000
+44,000
| +10% | +$3.37M | 2.68% | 8 |
|
|
2018
Q3 | $39M | Buy |
456,000
+332,000
| +268% | +$33.3M | 2.34% | 12 |
|
|
2018
Q2 | $14.4M | Sell |
124,000
-8,000
| -6% | -$798K | 0.94% | 34 |
|
|
2018
Q1 | $10.7M | Buy |
132,000
+44,000
| +50% | +$3.39M | 0.82% | 40 |
|
|
2017
Q4 | $5.16M | Sell |
88,000
-20,000
| -19% | -$1M | 0.51% | 50 |
|
|
2017
Q3 | $5.05M | Sell |
108,000
-156,000
| -59% | -$6.27M | 0.6% | 49 |
|
|
2017
Q2 | $9.5M | Sell |
264,000
-8,000
| -3% | -$256K | 1.21% | 35 |
|
|
2017
Q1 | $8.38M | Buy |
272,000
+44,000
| +19% | +$1.37M | 1.73% | 24 |
|
|
2016
Q4 | $7.64M | Buy |
228,000
+16,000
| +8% | +$459K | 1.81% | 28 |
|
|
2016
Q3 | $5.64M | Sell |
212,000
-28,000
| -12% | -$650K | 1.81% | 22 |
|
|
2016
Q2 | $5.29M | Buy |
+240,000
| New | +$6.28M | 2.01% | 21 |
|
Other funds holding ENTA
KAM
FCM
RCM
Armistice Capital's ENTA Position: Q4 2024 in Review
Armistice Capital sold out of Enanta Pharmaceuticals (ENTA) in Q4 2024, closing a stake of 1,000,000 shares — an estimated $10.4M sold.
Armistice Capital first reported a position in ENTA in Q2 2016 and held it in 34 quarters. The position peaked at $107M in Q3 2022. 107 funds tracked by Wall St. Rank hold ENTA as of Q4 2024.
- Armistice Capital reported no remaining Enanta Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
- Armistice Capital sold 1,000,000 Enanta Pharmaceuticals shares in Q4 2024, an estimated $10.4M.
- Armistice Capital first reported a position in Enanta Pharmaceuticals in Q2 2016 and held it in 34 quarters.
- Armistice Capital's Enanta Pharmaceuticals position peaked at $107M in Q3 2022.
- 107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2024.
Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.